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Abstract: The majority of patients with acute myeloid leukemia (AML) are elderly and
have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent
that induces differentiation and apoptosis of leukemic cells, is a well-tolerated alternative to
aggressive chemotherapy. It is currently FDA-approved for myelodysplastic syndrome, including
patients with 20%–30% bone marrow blasts. Recent clinical attention has focused on evaluating
decitabine as frontline therapy for untreated high-risk elderly AML patients. A large randomized
international phase III study comparing decitabine to supportive care and cytarabine in elderly
AML patients demonstrated significantly improved complete remission rates, but the survival
difference did not reach significance. Due to this, decitabine did not achieve FDA approval
for AML, but continues to be used off-label. Current research is focused on further defining
subgroups of elderly AML patients who may derive greater benefit from decitabine therapy
and combining it with other low-intensity active agents for AML.
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The majority of the approximately 14,500 individuals diagnosed with acute myeloid
leukemia (AML) each year in the US are over age 60 years, and a third are over age
75 years.1 Unfortunately, advanced age is one of the most adverse prognostic factors
in AML, in part because older patients have difficulty tolerating chemotherapy due
to comorbidities, concomitant end-organ dysfunction, and poor performance status.
However, the biology of the disease in the elderly also contributes to poor outcomes.
AML in older patients can be secondary to overt or unrecognized myelodysplastic
syndromes (MDS), which tends to be less chemoresponsive. AML in the elderly is
also associated with complex and monosomal karyotypes with adverse cytogenetics,2–6
fewer favorable mutations such as NPM1,5 and a multidrug-resistant phenotype.6 Even
within each molecular risk group, older patients tend to have a more chemoresistant
disease, the precise mechanisms for which are unknown.
Due to the high morbidity and relatively low efficacy associated with standard
induction chemotherapy for elderly patients, there has been considerable interest in the
hypomethylating agents 5-azacitadine and decitabine as frontline therapy. Both drugs
were originally developed as cytarabine analogues to be used at high doses as antimetabolites, until their ability to target epigenetic changes that contribute to leukemogenesis
was discovered. While their precise mechanism of action is unclear, it is thought that
by reversing methylation-induced gene expression and perhaps through direct cytotoxicity, both agents can reactivate tumor-suppressor genes and promote apoptosis.7,8
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They are currently FDA-approved for MDS, after trials
demonstrated complete and partial remissions lasting several
months when compared to supportive therapy, with a tolerable toxicity profile.9–11 This article addresses the clinical
evidence, toxicity, and potential role of decitabine in previously untreated elderly patients with AML.

Treatment options for elderly
AML patients
There are several distinct therapy pathways for elderly
adults diagnosed with AML. For patients age 60–65 years
with good performance status and favorable cytogenetics, induction with the 7+3 regimen of cytarabine and an
anthracycline (daunorubicin, idarubicin, or mitoxantrone)
offers the possibility of durable disease control and may be
the best treatment option. In fact, a study by Löwenberg et al
suggested that these patients may benefit from higher doses
of anthracyclines (90 mg/m2/day instead of 45 mg/m2/day of
daunorubicin) with reported complete remission (CR) rates of
64% versus 54%.12 However, the benefits of the higher-dose
anthracycline were limited to patients under 65 years old.
Responses can be consolidated with additional cycles of
cytarabine or reduced-intensity conditioning allogeneic stem
cell transplantation.
While remission rates of 40%–50% with the 7+3 regimen
have been noted in elderly patients in clinical trials, median
survival is still dismal at 7–12 months, with a 7% 2-year survival in some subgroups.13–15 Induction chemotherapy is also
associated with significant upfront morbidity, with 4-week
mortality of 15%–30% in select elderly populations.13,14,16
In addition, many elderly patients are unable to undergo
allogeneic stem cell transplantation due to poor performance
status, comorbidities, and older sibling age, leading to transplant rates of 5% in one prospective feasibility study.17 For
elderly patients with intermediate- or high-risk cytogenetics
or unfavorable molecular markers who are not candidates
for transplantation, the limited curative potential and high
toxicity of standard chemotherapy has led many patients and
oncologists to pursue alternative options. For many years, the
primary option was supportive care and referral to a hospice.
This path was chosen by over two-thirds of older adults with
AML during the 1990s and was associated with a median
survival of only 1 month.18
A number of intermediate-intensity therapy regimens have
now been investigated for the large subset of elderly patients
over 65 years old who are unlikely to benefit from aggressive induction therapy but who desire treatment. While not
curative, these agents offer the promise of remission and/or
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stabilization of counts, allowing additional months of quality
life outside the hospital. Low-dose cytarabine (LDAC) has
been established as the prototype of this middle route after a
randomized study by Burnett et al showed higher rates of CR
(18% versus 1%) and overall survival compared to supportive
care in a population of elderly adults who were not candidates
for conventional therapy.19 However, overall survival was
only 4 months for the LDAC cohort, a modest improvement over the 3 months seen in the hydroxyurea group.
Additionally, for patients with adverse cytogenetics, no benefit
in remission or survival was noted. Gemtuzumab ozogamicin
had shown some promise in elderly patients,20 but it was
withdrawn from the market in 2010 after a postmarketing
confirmatory phase III trial was terminated for lack of definitive benefit and enhanced toxicity.21 Aside from clinical trials,
the current National Comprehensive Cancer Care guidelines
suggest clofarabine, 5-azacitidine, and decitabine as alterative
options for this population of patients.22 Clofarabine23 and
5-azacitadine24 have been reviewed elsewhere.

Decitabine
Decitabine (5-aza-2′-deoxycytidine or 5-Aza-Cdr) is a cytosine analogue that was first synthesized in the early 1960s
by Pliml and Sorm and is currently marketed as Dacogen®
by Eisai (Tokyo, Japan). It differs from deoxycytidine by
the substitution of nitrogen for carbon at the 5-position
of the pyrimidine ring (Figure 1). It was noted to have an
antileukemic effect in cell lines, with more potency in vitro
than cytarabine.25 Initially, its cytotoxicity was attributed to
its ability to impair DNA synthesis and cause DNA damage
similar to other antimetabolites. Early clinical experience
therefore utilized this drug in high doses (up to 1,000 mg/m2
per cycle) alone and in combination with anthracyclines,
with considerable hematological and nonhematological
toxicity.26,27
Preclinical studies in the 1980s, however, demonstrated
that at low doses, decitabine induced differentiation by
reversing DNA methylation-induced gene silencing.28 Once
inside a cell, decitabine is phosphorylated and activated by
the enzyme deoxycytidine kinase to its triphosphate form
aza-dCTP.29,30 It then competes with and replaces cytosine
in the CpG (cytosine–guanosine dinucleotide) islands that
occur in clusters in promoter regions. During subsequent cell
divisions, aza-dCTP inhibits methylation of the promoter by
forming a covalent bond with the enzyme DNA methyltransferase (DNMT), and thereby traps and contributes to degradation of the enzyme.29,31 Since methylation-induced aberrant
transcriptional silencing of tumor-suppressor genes has been
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Figure 1 Comparison of the chemical structures of decitabine (5-aza-2′-deoxycytidine) and cytarabine with that of the nucleotide deoxycytidine.

implicated in the pathogenesis of a variety of human cancers,
including MDS and AML,32–34 this led to clinical interest in
using low-dose decitabine in these malignancies.

Phase III studies in MDS
Two phase III studies of decitabine in the MDS population
warrant mention in this review, since they included patients
with 20%–30% bone marrow blasts who were initially
classified as the refractory anemia with excess blasts in
transformation subset of MDS. This group was reclassified
as AML by the WHO criterion in 2002. The first study by
Kantarjian et al in 2006 randomized 170 patients with highrisk MDS to supportive care with transfusions or decitabine
at a dose of 15 mg/m2 intravenously (IV) every 8 hours for
3 days (total dose per cycle of 135 mg/m2) every 6 weeks.11
Thirty-one of the 170 patients in this study (18%) met the
WHO criterion for AML. Patients in the decitabine arm had a
17% response rate (9% CR), compared to no responses noted
in the supportive-care group. An additional 13% of patients
on decitabine achieved some hematological response.
Responses were durable, lasting a median of 10.3 months, and
were associated with transfusion independence. Decitabine
therapy was also associated with a trend towards longer time
to AML progression or death (median 12.1 vs 7.8 months),
but this did not reach statistical significance (P=0.16).
Among the patients with .20% bone marrow blasts, three
of the 17 patients randomized to the decitabine arm (19%)
achieved either a complete or partial response. Decitabine
was largely well tolerated, with hematological toxicities
being the most common. Based on these data, decitabine
gained FDA approval for MDS.
A second randomized multicenter phase III European
study published in 2011 compared decitabine to supportive
care in 233 patients with MDS, including 75 patients (32%)
with 20%–30% bone marrow blasts.35 Decitabine was given
at the same dose (15 mg/m2 IV three times a day for 3 days

Cancer Management and Research 2014:6

as part of a 6-week cycle). Response rates were similar
to the previous study, with 13% of patients on decitabine
achieving CR, 6% achieving partial remission, and 15%
achieving hematological improvement. Again, although
there was a trend towards improved overall survival (median
of 10.1 months versus 8.5 months, P=0.38) and AML-free
survival (median of 8.8 versus 6.1 months, P=0.24), it did
not reach statistical significance. However, progression-free
survival (6.4 months versus 3.0 months) was significantly
different (P=0.004). Decitabine was also associated with
improvements in patient-reported quality-of-life measures.
Again, the primary toxicity remained hematological, with
25% of patients on the decitabine arm experiencing grade
3/4 febrile neutropenia compared to 7% on the supportivecare arm.

Phase I studies in AML
Three phase I studies of low-dose decitabine in patients
with leukemia examined safety and response to different
decitabine regimens, including combination therapy with
other low-intensity agents. The majority of patients in these
studies were elderly, and most had relapsed AML. They set
the stage for the phase II and III studies described further,
and are summarized in Table 1.
The first phase I study, by Issa et al in 2004, examined
four different regimens of decitabine in 50 patients with
hematological malignancies, of whom nearly three-quarters
carried a diagnosis of AML.36 Patients were treated with 5, 10,
15, or 20 mg/m2 of decitabine daily for 10–20 days. Overall,
response was noted in 32% of patients, with CR in 18%.
Among the AML patients, 14% achieved CR and 8% had
CR with incomplete platelet recovery (CRp). The 15 mg/m2
10-day dosing was noted to be optimal, with responses
observed in 65% of patients. Treatment was well tolerated,
with severe elevations in liver enzymes in six patients as the
primary nonhematological toxicity.
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Table 1 Summary of clinical trials examining low-dose decitabine in acute myeloid leukemia (AML)
Phase

Decitabine regimen

Patients
with AML

Median
age (years)

CR* (%)

Median survival
(months)

Issa et al36

I

37

60

21.6

NR

Garcia-Manero et al37,**
Blum et al38,**

I/II
I

48
25

60
70

18.8
32.0

NR
NR

Cashen et al39
Blum et al42
Lübbert et al43

II
II
II

55
53
227

74
74
72

25.4
64.2
13.2

7.7
12.7
5.5

Kantarjian et al44

III

Varied, with 15 mg/m2 daily for 10 days
noted to be optimal
15 mg/m2 daily for 10 days every 4 weeks
Varied, with 20 mg/m2 daily for 10 days
every 4 weeks noted to be optimal
20 mg/m2 daily for 5 days every 4 weeks
20 mg/m2 daily for 10 days every 4 weeks
15 mg/m2 three times daily for 3 days
every 6 weeks
20 mg/m2 for 5 days every 4 weeks
vs LDAC or supportive care

485 (242 with
decitabine)

73

17.8 vs 7.8
(P=0.001)

7.7 vs 5 (P=0.11)

Notes: *CR rate includes patients with complete remission with incomplete count recovery, except for Lübbert (2010), where only CR was included. CR with incomplete
count recovery in this study was combined with partial remission. **Some patients were treated with valproic acid in addition to decitabine.
Abbreviations: CR, complete remission; NR, not reported; LDAC, low-dose cytarabine.

A second phase I/II study by Garcia-Manero et al
treated 54 AML and MDS patients with a decitabine dose
of 15 mg/m2/day for 10 days, in combination with the
histone deacetylase inhibitor valproic acid.37 Valproic acid
was escalated to 50 mg/kg/day, with an acceptable level of
neurotoxicity. The majority of the patients had AML (48 of
54), with a median age of 60 years. Overall, 22% of patients
had a response, including ten with CR and two with CRp.
Notably, 50% of the previously untreated AML patients had a
response. Overall survival was 6 months, but median survival
was as high as 15.3 months in the responders. The primary
nonhematological toxicity was anorexia and confusion, with
the latter primarily attributed to the valproic acid.
A third phase I study by Blum et al also examined decitabine in combination with valproic acid in AML patients.38
Twenty-five patients (twelve untreated, 13 relapsed) with
AML with a median age of 70 years were enrolled. Two
doses of decitabine were administered (15 mg/m2/day and
20 mg/m2/day) for 10 days, and the higher dose was defined
as the optimum biological dose, as it induced higher rates
of reexpression of ER and P15 (genes methylated in AML).
Three different valproic acid dosing regimens were then
combined with the 20 mg/m2 dose of decitabine. Confusion
again was the primary toxicity observed with valproic acid,
especially with doses above 20 mg/kg/day. The overall
response rate was 44% in the intention-to-treat group and
52% (eleven of 21) in assessable patients. The addition of
valproic acid did not appear to confer any additional benefit.
The authors concluded that given valproic acid’s narrow
therapeutic index and toxicity, decitabine alone or in combination with alternative histone-deacetylating agents should
be the focus of future studies.
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Phase II studies in AML
Three phase II studies established decitabine’s activity
in elderly AML patients. In a multicenter study, Cashen
et al treated 55 newly diagnosed older AML patients with
intermediate- or poor-risk cytogenetics with decitabine
20 mg/m2/day for 5 days, repeated on a 4-week cycle.39 The
5-day decitabine regimen was drawn from studies that had
found this outpatient schedule to be effective and well tolerated in MDS patients.40,41 The study population was a highrisk group, with a median age of 74 years, 42% secondary
AML, and median baseline bone marrow blast percentage of
50%. After a median of three cycles of decitabine, the overall
response rate was 25% and an additional 29% had stable
disease. The majority of the responders achieved morphological CR (13 of 14), with one patient achieving CR with incomplete count recovery (CRi). Response rates were preserved
in patients with poor-risk cytogenetics, a subgroup that has
historically derived limited benefit with other agents such as
LDAC.19 While a majority of the study population did not have
proliferative AML (median white blood cell count 2.7), it was
notable that only one (7%) of 14 patients with a peripheral
blast count over 1,000/µL achieved CR. Among patients with
a cytogenetic abnormality at baseline, five of 25 achieved
cytogenetic remission. The time to achieve CR was 4.5 cycles,
favoring differentiation rather than cytotoxicity as the primary
mechanism of action and indicating that persistence with the
medication is needed if the drug is tolerated and the disease is
stable. Median survival was 7.7 months for the full cohort, but
was 14 months for the responders. The drug was fairly well
tolerated, with myelosuppression, febrile neutropenia (29%),
and fatigue as the major toxicities and a 30-day mortality of
7%. This promising response rate and toxicity profile set the
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stage for the use of this decitabine dose in the phase III study
described later.
A single-center phase II trial by Blum et al increased the
first-cycle dose of decitabine to 20 mg/m2/day for 10 days,
with cycle length reduced to 5 days if response was observed.42
Fifty-three older patients with newly diagnosed AML were
treated. In contrast to the Cashen et al study,39 this study
population included patients with good-risk prognostic factors (19% of enrollees). The median age was 74 years, and
36% of patients had secondary AML. After treatment with
a median of four cycles of decitabine, the response rate was
64% (34 of 53), with 49% CR and 15% CRi. The response
rate was similarly high across all cytogenetic subgroups,
and was even observed in patients with high circulating
blasts, where the response was 50% for patients with a white
blood cell count .50,000. Interestingly, in eleven patients
with monosomy 7 or deletion of 7q, the response rate was
remarkable – 91%. Median survival was 12.7 months, and
disease-free survival for patients in CR was 10.6 months.
The primary toxicity remained myelosuppression. The higher
dose of decitabine (10-day cycle), along with longer exposure
to the drug (four cycles), resulted in higher rates of febrile
neutropenia compared to prior studies (68%), but overall
decitabine was well tolerated, with only one death (2%) within
30 days of therapy. The authors correlated response with
pretreatment levels of microRNA29b (miR29b), an miRNA
that specifically inhibits DNA methyltransferase expression.
Patients who responded to decitabine tended to have higher
levels of miR29b (P=0.02), indicating that it could potentially
be used as a predictive marker for response.
A third large phase II study, by Lübbert et al, treated 227
elderly AML patients at nine centers in Europe, with an MDS
dosing schedule of decitabine at 15 mg/m2 every 8 hours for
3 days as part of a 6-week cycle.43 Patients who had stable
disease or antileukemic effect after cycle 1 were given alltrans retinoic acid (ATRA) at the next cycle, to determine if
hypomethylation promoted ATRA susceptibility even in the
absence of PML–RARA fusion (based on preclinical studies).
The study population had poor prognostic indicators, with a
median age of 72 years, 51% secondary AML, 32% adverse
cytogenetics, and median bone marrow blasts of 56%. After
receiving a median of two cycles, objective response was
achieved in 26% (59 patients), with CR in 30 patients (13%)
and partial remission (5%–25% bone marrow blasts or CRi)
in 29 additional participants. A further 26.4% of patients
responded with “antileukemic effect,” defined as 25%
reduction in blasts without meeting the criterion for partial
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remission, and another 25% had stable disease. Response
rates were similar in patients with adverse cytogenetics
(29%) and those with the very poor-risk monosomal karyotype (37%). Median survival was 5.5 months. The inclusion
of ATRA with cycle 2 did not prolong survival in patients.
Decitabine was again well tolerated, with 33.5% of patients
experiencing grade 3 or 4 toxicity. Mortality after the first
cycle was 12.8%. While the CR rate in this study was lower
than previous ones, at 13%, this may be reflective of the
study design, which called for application of four courses
of therapy and then optional maintenance therapy without
systematic recording of improvement in response rate while
on maintenance. The authors concluded that decitabine was
well tolerated, with encouraging responses noted in patients
with poor-risk cytogenetics.

Phase III study in AML
The phase III randomized trial examining outcomes with
decitabine in elderly AML patients was an open-label study
of 485 patients in 15 countries randomized in a 1:1 fashion to
decitabine or their treatment choice (TC) of either LDAC or
supportive care.44 The majority of the patients in the TC arm
received LDAC therapy (218 of the 243 patients) at a dose
of 20 mg/m2 daily subcutaneously for 10 days as a 4-week
cycle. Notably, the daily LDAC dosing was lower than
prior studies, including those by Burnett et al (which used a
twice-daily regimen),19 with the reduction done for dosing
convenience. The decitabine dose was the same as that used
in the phase II study by Cashen et al,39 at 20 mg/m2/day IV
for 5 days as a 4-week cycle. The population was high-risk,
with an average age of 73 years, median bone marrow blast
count of 46%, and 35.3% with secondary AML. Patients with
favorable cytogenetics were excluded. The primary end point
was overall survival, which was prospectively specified to
occur at 385 deaths (80%), and the study was powered to
detect a 25% reduction in mortality. Secondary end points
included the combination of CR and CRp and safety.
While there was a trend towards improved survival with
decitabine (7.7- versus 5.0-month median survival) at the
prospectively defined time point, the hazard ratio of 0.85 was
not statistically significant (P=0.108). However, statistical
significance was achieved in a follow-up ad hoc analysis performed 1 year later, when 92% of deaths had occurred. At that
time point, the median survival remained the same, and the
hazard ratio was 0.82 (P=0.037). Also, by censoring patients
who received subsequent antileukemic therapy (37.6%
patients in the decitabine arm and 44.4% in the TC arm),
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overall survival was again significant (8.5- versus 5.3-month
median survival, P=0.044).
Multivariate analysis of survival demonstrated decitabine superiority in patients over 75 years old, those with
an Eastern Cooperative Oncology Group performance status
of 2, and those with over 30% marrow blasts. Interestingly,
no difference between decitabine and LDAC was noted in
the subgroup with 20%–30% marrow blasts. This group
did derive benefit from decitabine in the phase III studies
of decitabine in MDS,11,34,35 but the control group in those
studies was supportive care alone, which may account for
the discrepancy in results.
Regarding the secondary end points, patients on decitabine had significantly improved rates of CR and CRp (17.8%
vs 7.8% in the TC group) at the prespecified cutoff, with an
odds ratio of 2.5 (1.4–4.8, P=0.001). The safety profile of
decitabine was similar to LDAC, with the majority of patients
in both arms experiencing some grade 3 or 4 toxicity while
taking the study drug. The primary toxicity was hematologic,
with a higher incidence of thrombocytopenia (40% vs 32%),
anemia (34% vs 25%), and neutropenia (32% vs 18%) in the
decitabine arm. Infectious complications were also slightly
higher in the decitabine group, with febrile neutropenia
(32% vs 22%) and pneumonia (21% vs 18%) being the two
most common. However, the authors noted that patients in
the decitabine arm were exposed to the study medication
longer than the LDAC group (4.4 months vs 2.4 months),
which likely contributed to greater reporting of adverse
events. Discontinuation of the study drug was similar for
decitabine (6%) and cytarabine (8%). The authors concluded
that decitabine was at least as well tolerated as LDAC, with
no major differences in safety.
While this phase III study demonstrated decitabine to be
an effective alternative to LDAC for high-risk elderly patients
with AML, its results have been fraught with controversy.
Based on the same trial data, the FDA Oncological Drug
Advisory Committee (ODAC) voted against approving
decitabine for the indication of AML in elderly patients, but
the European Medicines Agency Committee for Medicinal
Products for Human Use approved it. The controversy stems
largely from difficulty in assigning superiority to decitabine
when the survival differences at the prospectively specified
end point did not reach significance. While mature data
with more deaths included did show significantly improved
survival with decitabine, the fact that it was an unplanned
analysis led to concern for a false-positive result.45 The FDA
panel also noted that the CR rate with LDAC (8.4%) was
lower than prior studies that had reported 15%–20%.13,19,44,45,46
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While comparisons across trials are fraught with bias due to
differences in patient characteristics, the fact that a lower
dose of cytarabine was used does raise the possibility that
suboptimal cytarabine dosing in the control arm contributed
to this lower CR rate. Finally the ODAC panel also expressed
concern that in the Western European study population
(where LDAC is more frequently used), the survival trend
favored LDAC versus decitabine (median survival 12.5
versus 9 months, P=0.91).45 However the authors refuted
the merits of this argument by noting that the patients in the
decitabine arm in Europe had worse baseline characteristics
and many patients in the TC arm in Europe subsequently
received further therapy with hypomethylating agents, making it difficult to derive any conclusions from this subgroup
analysis.47
Prior studies have suggested that certain subgroups of
elderly AML patients benefit more from hypomethylating
agents. The phase II data by Cashen et al39 and data from
azacitidine46 have suggested that hypomethylating agents
may be particularly beneficial in hypoproliferative AML.
However, the data from the phase III study did not analyze
peripheral blast count as an independent variable. Additional
studies have suggested that decitabine may also confer greater
benefit to subgroups with specific molecular characteristics.
Monosomal karyotype patients, who have worse outcomes
with standard cytotoxic chemotherapy, 48 had impressive
response rates to decitabine in phase II AML studies42,43
and to azacitidine in MDS.49,50 However, outcome based on
karyotype was not provided in the phase III study either, and
could be a subject of further investigation.

Decitabine as a bridge
to transplant in AML patients
A single-center study has explored decitabine as a bridge to
reduced-intensity allogeneic transplant for elderly patients
with a good performance status.51,52 Traditionally, standard
induction chemotherapy has been used to achieve CR
prior to transplant. Lübbert et al tested decitabine instead,
with the hypothesis that the drug’s milder toxicity would
reduce up-front mortality and may in fact enhance the graftversus-leukemia effect by upregulating human leukocyteantigen expression.51 They reported their experience with
15 consecutive elderly patients (nine with AML and six
with MDS), with a median age of 69 years, treated with
decitabine at 15 mg/m2 every 8 hours for 3 days as part of
a 6-week cycle. After a median of five cycles of decitabine,
five patients achieved CR. Allografting was performed after
conditioning with a reduced-intensity regimen of fludarabine,
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carmustine, and melphalan. The median blast percentage for
study population was 24% both at the start of induction and
at the time of transplant. After transplant, one patient died
of infection before engraftment, but eight of ten patients for
whom data were available had full donor chimerism at 30 and
100 days after transplant. The rates of graft-versus-host disease were not higher than expected. While median duration
of CR after transplant was only 5 months, survival at 1 year
was 47%, at 2 years was 30%, and three patients continued
to be alive over 5 years after their transplant at the time of
publication of their update.52 While this was only a small
single-center study, it supports further investigation of decitabine induction chemotherapy as a bridge to transplant.

Conclusion and future directions
The hypomethylating agent decitabine at low doses promotes
cellular differentiation by reversing epigenetic suppression
of genes, and has shown efficacy in producing remissions
lasting several months in a subset of elderly patients with
MDS and AML. It can be given as outpatient therapy daily
for 5–10 days per cycle. It is relatively well tolerated in the
elderly population, with myelosuppression and febrile neutropenia as the primary toxicity. Multiple cycles of decitabine
may be needed to achieve remission, and therefore treatment
should be continued as long as the disease is stable. A recent
phase III study demonstrated higher rates of complete remission with decitabine therapy compared to low-dose cytarabine
in elderly AML patients, but the survival difference failed to
reach significance.44,45
At present, the role of decitabine in the treatment of
elderly AML patients is yet to be fully defined. At this
time, there are multiple ongoing studies to further delineate
decitabine’s efficacy in elderly AML patients.53 Given its
relatively mild toxicity, decitabine continues to be an attractive agent for combination therapy with other antileukemic
agents. Phase I and II studies examining decitabine in combination with low-dose cytarabine (NCT01829503), bortezomib (NCT01420926), plerixafor (NCT01352650), and
the tyrosine-kinase inhibitors midostaurin (NCT01846624)
and sorafenib (NCT01861314) are all currently under way.53
There continues to be interest in combining decitabine with
newer, less toxic histone deacetylase inhibitors, such as
AR-42 (NCT01798901), with the rationale that promoting
histone acetylation would lead to an open chromatin configuration and permit repressed gene expression synergistically,
as has been noted in preclinical studies.54 Correlative studies
are also ongoing to define cytogenetic and molecular characteristics that predict response to decitabine (NCT01687400).
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A retrospective analysis of DNMT3A mutation status and
decitabine response demonstrated a response rate of 75% in
a cohort of eight patients, but this needs further validation
in larger studies.55 An observation from the phase II data
that monosomal karyotype elderly AML patients may have a
disproportionate benefit from decitabine also warrants further
attention. An oral formulation of decitabine is also under
investigation,56 and may provide a more convenient option
for elderly patients. Another trial comparing a 10-day versus
5-day decitabine regimen is also under way, given the higher
response rates in the single-center phase II study with the
10-day regimen (NCT01786343). Decitabine may also have
a role as maintenance therapy or as a bridge to allogeneic
stem cell transplant.51,52
In conclusion, elderly AML patients with intermediateand poor-risk cytogenetics continue to have a very poor
prognosis. Standard induction chemotherapy has a high
up-front mortality in this population, with a high likelihood
of relapse even if remission is achieved. Decitabine is a welltolerated therapeutic alternative, and recent clinical evidence
has shown it to be effective in producing remissions lasting
several months or disease stabilization in a subset of this
population. Further studies are needed to define which subset
of elderly patients is most likely to derive maximal benefit
from single-agent decitabine therapy.
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